Envestnet Portfolio Solutions’s Corcept Therapeutics CORT Stock Holding History

Envestnet Portfolio Solutions’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$923K	Buy	10,617 +184	+2%	+$11.1K	﹤0.01%	746
2026 Q1	$421K	Sell	10,433 -1,927	-16%	-$72.1K	﹤0.01%	974
2025 Q4	$430K	Sell	12,360 -245	-2%	-$19.2K	﹤0.01%	1121
2025 Q3	$1.05M	Sell	12,605 -2,291	-15%	-$166K	﹤0.01%	720
2025 Q2	$1.09M	Buy	14,896 +9,822	+194%	+$712K	﹤0.01%	758
2025 Q1	$580K	Buy	+5,074	New	+$309K	﹤0.01%	988

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Envestnet Portfolio Solutions's CORT Position: Q2 2026 in Review

Envestnet Portfolio Solutions increased its Corcept Therapeutics (CORT) stake by 1.8% in Q2 2026, buying an estimated $11.1K and bringing the position to 10,617 shares worth $923K. The position accounts for ﹤0.01% of the portfolio, ranked #746.

Envestnet Portfolio Solutions first reported a position in CORT in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.09M in Q2 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Envestnet Portfolio Solutions held 10,617 shares of Corcept Therapeutics worth $923K as of Q2 2026.
Envestnet Portfolio Solutions bought 184 Corcept Therapeutics shares in Q2 2026, an estimated $11.1K.
Corcept Therapeutics made up ﹤0.01% of Envestnet Portfolio Solutions's portfolio in Q2 2026, its #746 holding.
Envestnet Portfolio Solutions first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 6 quarters since.
Envestnet Portfolio Solutions's Corcept Therapeutics position peaked at $1.09M in Q2 2025.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Envestnet Portfolio Solutions's 13F filing for Q2 2026, filed 20 Jul 2026.